GlassScriptPhysician profile
Mary R Strickler
NPI 1649710989
$3,364.04
in general payments reported to CMS, 2019-2025
35 companies · $42.01 in 2025
The $42.01 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $469 · 2022: $529 · 2023: $770 · 2024: $1,553 · 2025: $42.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,365.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $733.92 | 2021-2024 | |
| Novo Nordisk INC | $385.38 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $286.70 | 2021-2025 | Xifaxan |
| Lilly USA, LLC | $233.79 | 2021-2024 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $230.08 | 2021-2024 | Airsupra, Farxiga, Fasenra |
| Pfizer INC. | $196.87 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $122.63 | 2022 | |
| Glaxosmithkline, LLC. | $120.46 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Xeris Pharmaceuticals, INC. | $95.88 | 2022-2024 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $91.05 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.54 | 2021-2024 | Spiriva Respimat, Jardiance, Stiolto Respimat |
| Inspire Medical Systems, INC. | $75.77 | 2024-2025 | Inspire |
| Axsome Therapeutics, INC. | $71.47 | 2024 | Auvelity |
| Amgen INC. | $65.78 | 2022-2023 | Prolia, Evenity |
| Boston Scientific Corporation | $55.11 | 2024 | Wavewriter Alpha Prime 16 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $48.90 | 2021 | |
| Sumitomo Pharma America, INC. | $46.46 | 2023-2024 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $42.86 | 2022 | |
| Esperion Therapeutics, INC. | $38.80 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $35.36 | 2022 | |
| Janssen Pharmaceuticals, INC | $32.95 | 2021-2023 | Xarelto |
| Dexcom, INC. | $27.87 | 2023 | Dexcom G6 Transmitter |
| Lundbeck LLC | $25.05 | 2024 | Vyepti |
| Astellas Pharma US INC | $24.63 | 2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $22.47 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $21.65 | 2022 | |
| Philips North America LLC | $19.93 | 2024 | (Ck7) Extended Holter |
| Azurity Pharmaceuticals, INC. | $19.05 | 2023 | Horizant |
| Jazz Pharmaceuticals INC. | $16.67 | 2021 | |
| Mylan Specialty L.P. | $16.46 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.28 | 2021 | |
| Antares Pharma, INC. | $14.62 | 2024 | Xyosted |
| Amarin Pharma, INC. | $14.07 | 2021 | |
| Allergan, INC. | $13.78 | 2021 | |
| Merck Sharp & Dohme LLC | $11.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Strickler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.